Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 717

1.

Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.

Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ.

Inflamm Bowel Dis. 2019 Oct 23. pii: izz241. doi: 10.1093/ibd/izz241. [Epub ahead of print]

PMID:
31644790
2.

Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease.

Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackleton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR.

Clin Gastroenterol Hepatol. 2019 Aug 29. pii: S1542-3565(19)30921-8. doi: 10.1016/j.cgh.2019.08.046. [Epub ahead of print]

PMID:
31473359
3.

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.

Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G.

Gastroenterology. 2019 Oct;157(4):1019-1031.e7. doi: 10.1053/j.gastro.2019.06.037. Epub 2019 Jul 4.

4.

IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.

Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S.

J Crohns Colitis. 2019 Jun 3. pii: jjz110. doi: 10.1093/ecco-jcc/jjz110. [Epub ahead of print]

PMID:
31158271
5.

Corrigendum: Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome.

Yang L, Tang S, Baker SS, Arijs I, Liu W, Alkhouri R, Lan P, Baker RD, Tang Z, Ji G, Rutgeerts P, Vermeire S, Zhu R, Zhu L.

Inflamm Bowel Dis. 2019 Oct 18;25(11):e154. doi: 10.1093/ibd/izz023. No abstract available.

PMID:
30958546
6.

Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.

Philip G, Cornillie F, Adedokun JO, Melsheimer R, Rutgeerts P, Colombel JF, Marano C.

J Crohns Colitis. 2019 Sep 27;13(10):1257-1264. doi: 10.1093/ecco-jcc/jjz052.

PMID:
30847474
7.

Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.

Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G.

Inflamm Bowel Dis. 2019 Aug 20;25(9):1532-1540. doi: 10.1093/ibd/izz003.

PMID:
30753466
8.

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF.

J Crohns Colitis. 2019 May 27;13(6):725-734. doi: 10.1093/ecco-jcc/jjy223.

9.

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

Verstockt S, De Hertogh G, Van der Goten J, Verstockt B, Vancamelbeke M, Machiels K, Van Lommel L, Schuit F, Van Assche G, Rutgeerts P, Ferrante M, Vermeire S, Arijs I, Cleynen I.

J Crohns Colitis. 2019 Jul 25;13(7):916-930. doi: 10.1093/ecco-jcc/jjz007.

PMID:
30657881
10.

Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome.

Yang L, Tang S, Baker SS, Arijs I, Liu W, Alkhouri R, Lan P, Baker RD, Tang Z, Ji G, Rutgeerts P, Vermeire S, Zhu R, Zhu L.

Inflamm Bowel Dis. 2019 Mar 14;25(4):722-731. doi: 10.1093/ibd/izy359.

PMID:
30517639
11.

No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of the Rutgeerts' Scoring System.

Rivière P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, de Buck van Overstraeten A, Denost Q, Wolthuis A, D'Hoore A, Laharie D, Ferrante M.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1643-1645. doi: 10.1016/j.cgh.2018.09.047. Epub 2018 Oct 4.

PMID:
30291910
12.

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.

Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1525-1532.e1. doi: 10.1016/j.cgh.2018.09.033. Epub 2018 Sep 26.

13.

Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.

Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F.

Inflamm Bowel Dis. 2019 Jan 1;25(1):163-171. doi: 10.1093/ibd/izy229.

PMID:
29982631
14.

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.

Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE.

Gastroenterology. 2018 Oct;155(4):1008-1011.e8. doi: 10.1053/j.gastro.2018.06.077. Epub 2018 Jul 4.

15.

Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.

Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C.

J Crohns Colitis. 2018 Jun 18. doi: 10.1093/ecco-jcc/jjy079. [Epub ahead of print]

PMID:
29917070
16.

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ.

Gastroenterology. 2018 Oct;155(4):1045-1058. doi: 10.1053/j.gastro.2018.06.035. Epub 2018 Aug 29.

PMID:
29909019
17.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG.

Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24.

18.

Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.

Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM.

Inflamm Bowel Dis. 2018 Apr 23;24(5):932-942. doi: 10.1093/ibd/izx082.

PMID:
29668919
19.

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1276-1283.e1. doi: 10.1016/j.cgh.2017.11.046. Epub 2017 Dec 1.

PMID:
29203225
20.

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H.

Aliment Pharmacol Ther. 2018 Jan;47(2):219-228. doi: 10.1111/apt.14420. Epub 2017 Nov 21.

21.

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.

Lancet. 2018 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31. Erratum in: Lancet. 2018 Dec 23;390(10114):2768.

PMID:
29096949
22.

Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.

Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I, Cleynen I.

Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.

23.

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.

Bisschops R, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G.

Gut. 2018 Jun;67(6):1087-1094. doi: 10.1136/gutjnl-2016-313213. Epub 2017 Jul 11.

PMID:
28698230
24.

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.

D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG.

Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1.

25.

Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Jun;112(6):975. doi: 10.1038/ajg.2017.120. Epub 2017 Apr 18. No abstract available.

PMID:
28417993
26.

Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.

Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K, Rutgeerts P, Vermeire S, Van Assche G.

J Crohns Colitis. 2017 Sep 1;11(9):1085-1089. doi: 10.1093/ecco-jcc/jjx048.

PMID:
28369329
27.

Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.

Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A.

J Crohns Colitis. 2017 Jul 1;11(7):811-819. doi: 10.1093/ecco-jcc/jjx005.

PMID:
28333187
28.

Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Oct;112(10):1584-1592. doi: 10.1038/ajg.2016.580. Epub 2017 Jan 10. Erratum in: Am J Gastroenterol. 2017 Jun;112(6):975.

PMID:
28071654
29.

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group.

N Engl J Med. 2016 Nov 17;375(20):1946-1960.

30.

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.

Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R.

J Crohns Colitis. 2017 Apr 1;11(4):425-434. doi: 10.1093/ecco-jcc/jjw178.

31.

Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.

Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S.

Gut. 2018 Jan;67(1):43-52. doi: 10.1136/gutjnl-2016-312293. Epub 2016 Oct 7.

PMID:
27802155
32.

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ.

J Crohns Colitis. 2017 Jan;11(1):35-46. doi: 10.1093/ecco-jcc/jjw133. Epub 2016 Jul 20.

33.

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.

Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M.

J Crohns Colitis. 2017 Jan;11(1):53-59. doi: 10.1093/ecco-jcc/jjw122. Epub 2016 Jul 11.

PMID:
27402915
34.

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year.

Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W.

Clin Transl Gastroenterol. 2016 Apr 28;7:e168. doi: 10.1038/ctg.2016.24.

35.

Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.

Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S.

J Crohns Colitis. 2016 Sep;10(9):1015-23. doi: 10.1093/ecco-jcc/jjw067. Epub 2016 Mar 28.

PMID:
27022161
36.

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group.

Gastroenterology. 2016 Jun;150(7):1568-1578. doi: 10.1053/j.gastro.2016.02.072. Epub 2016 Mar 3.

37.

The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG.

Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.

38.

Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease.

Amcoff K, Joossens M, Pierik MJ, Jonkers D, Bohr J, Joossens S, Romberg-Camps M, Nyhlin N, Wickbom A, Rutgeerts PJ, Tysk C, Bodin L, Colombel JF, Vermeire S, Halfvarson J.

J Crohns Colitis. 2016 Jun;10(6):695-702. doi: 10.1093/ecco-jcc/jjw021. Epub 2016 Jan 27.

PMID:
26818662
39.

Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.

Wouters MM, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, Valdez-Morales EE, Nasser Y, Van Veldhoven PP, Vanbrabant W, Van der Merwe S, Mols R, Ghesquière B, Cirillo C, Kortekaas I, Carmeliet P, Peetermans WE, Vermeire S, Rutgeerts P, Augustijns P, Hellings PW, Belmans A, Vanner S, Bulmer DC, Talavera K, Vanden Berghe P, Liston A, Boeckxstaens GE.

Gastroenterology. 2016 Apr;150(4):875-87.e9. doi: 10.1053/j.gastro.2015.12.034. Epub 2016 Jan 2.

PMID:
26752109
40.

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.

Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M.

Clin Gastroenterol Hepatol. 2016 Apr;14(4):543-9. doi: 10.1016/j.cgh.2015.11.014. Epub 2015 Dec 8.

PMID:
26681486
41.

Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.

Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S.

Ann Intern Med. 2016 Jan 5;164(1):10-22. doi: 10.7326/M15-0729. Epub 2015 Dec 8.

PMID:
26641955
42.

Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease.

Cleynen I, Konings P, Robberecht C, Laukens D, Amininejad L, Théâtre E, Machiels K, Arijs I, Rutgeerts P, Louis E, Franchimont D, De Vos M, Van Steen K, Georges M, Moreau Y, Vermeesch J, Vermeire S.

Inflamm Bowel Dis. 2016 Mar;22(3):505-15. doi: 10.1097/MIB.0000000000000623.

PMID:
26595553
43.

Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.

Coimbra AJ, Rimola J, O'Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL, Sandborn WJ, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J.

Aliment Pharmacol Ther. 2016 Jan;43(1):61-72. doi: 10.1111/apt.13453. Epub 2015 Nov 9.

44.

Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis.

Colombel JF, Ordás I, Ullman T, Rutgeerts P, Chai A, O'Byrne S, Lu TT, Panés J.

Gastroenterology. 2016 Feb;150(2):389-95.e3. doi: 10.1053/j.gastro.2015.10.016. Epub 2015 Oct 23.

PMID:
26526713
45.

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.

Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME.

Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.

46.

Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease.

Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J.

J Crohns Colitis. 2016 Apr;10(4):387-94. doi: 10.1093/ecco-jcc/jjv203. Epub 2015 Oct 29.

47.

Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC.

Machiels K, Sabino J, Vandermosten L, Joossens M, Arijs I, de Bruyn M, Eeckhaut V, Van Assche G, Ferrante M, Verhaegen J, Van Steen K, Van Immerseel F, Huys G, Verbeke K, Wolthuis A, de Buck Van Overstraeten A, D'Hoore A, Rutgeerts P, Vermeire S.

Gut. 2017 Jan;66(1):79-88. doi: 10.1136/gutjnl-2015-309398. Epub 2015 Sep 30.

PMID:
26423113
48.

Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.

Li Z, Vermeire S, Bullens D, Ferrante M, Van Steen K, Noman M, Bossuyt X, Rutgeerts P, Ceuppens JL, Van Assche G.

Inflamm Bowel Dis. 2015 Dec;21(12):2787-96. doi: 10.1097/MIB.0000000000000554.

PMID:
26383913
49.

Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.

de Bruyn M, Arijs I, De Hertogh G, Ferrante M, Van Assche G, Rutgeerts P, Vermeire S, Opdenakker G.

J Crohns Colitis. 2015 Dec;9(12):1079-87. doi: 10.1093/ecco-jcc/jjv148. Epub 2015 Sep 7.

PMID:
26351381
50.

Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease.

Vanhove W, Peeters PM, Staelens D, Schraenen A, Van der Goten J, Cleynen I, De Schepper S, Van Lommel L, Reynaert NL, Schuit F, Van Assche G, Ferrante M, De Hertogh G, Wouters EF, Rutgeerts P, Vermeire S, Nys K, Arijs I.

Inflamm Bowel Dis. 2015 Nov;21(11):2673-82. doi: 10.1097/MIB.0000000000000535.

PMID:
26313692

Supplemental Content

Loading ...
Support Center